1. Goldstein JL, Brown MS. Regulation of the mevalonate
pathway.
Nature. 1990; 343(6257): 425-430. Review.
[PubMed: 1967820]
2. Desvergne B, Michalik L, Wahli W. Transcriptional regulation
of metabolism. Physiol Rev. 2006;86(2):465-514.
Review.
3. Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical
and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics. 1993;91(5):915-921.
4. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia
D and periodic fever syndrome. The clinical spectrum in a series
of 50 patients. International Hyper-IgD Study Group. Medicine
(Baltimore). 1994;73(3): 133-144. Review.
5. Houten SM, Wanders RJ, Waterham HR. Biochemical and genetic
aspects of mevalonate kinase and its deficiency. Biochim
Biophys Acta. 2000;1529(1-3):19-32. Review.
6. Hoffmann GF, Sweetman L, Bremer HJ, et al. Facts and artefacts
in mevalonic aciduria: development of a stable isotope dilution
GCMS assay for mevalonic acid and its application to physiological
fluids, tissue samples, prenatal diagnosis and carrier detection. Clin
Chim Acta. 1991;198(3):209-227.
7. Drenth JP, van der Meer JW. Hereditary periodic fever. N
Engl J Med. 2001;345(24):1748-1757. Review.
8. Simon A, Drewe E, van der Meer JW, et al.
Simvastatin treatment
for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever
syndrome.
Clin Pharmacol Ther. 2004;75 (5):476-483.
9. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI,
Kastner DL. Favorable preliminary experience with etanercept in
two patients with the hyperimmuno-globulinemia D and periodic fever
syndrome.
Arthritis Rheum. 2003; 48(9):2645-2651.
[PubMed: 13130485]
10. Neven B, Valayannopoulos V, Quartier P, et al. Allogenic
bone marrow transplantation in mevalonic aciduria .
N
Engl J Med. 2007;356:2700-2703.
[PubMed: 17596604]
11. Ryan AK, Bartlett K, Clayton P, et al. Smith-Lemli-Opitz
syndrome: a variable clinical and biochemical phenotype. J
Med Genet. 1998;35 (7):558-565.
12. Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI. Clinical
and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz
syndrome and abnormal cholesterol metabolism. Am J Med Genet. 1997;68(3):263-269.
13. Waterham HR, Wanders RJ. Biochemical and genetic aspects
of 7-dehydro-cholesterol reductase and Smith-Lemli-Opitz syndrome. Biochim Biophys
Acta. 2000;1529(1-3):340-356. Review.
14. Witsch-Baumgartner M, Fitzky BU, Ogorelkova M, et al. Mutational
spectrum in the delta7-sterol reductase gene and genotype-phenotype
correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am
J Hum Genet. 2000;66(2):402-412.
15. Shackleton CH, Marcos J, Palomaki GE, et al. Dehydrosteroid
measurements in maternal urine or serum for the prenatal diagnosis
of Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet A. 2007;143(18):2129-2136.
16. McGaughran J, Donnai D, Clayton P, Mills K. Diagnosis of
Smith-Lemli-Opitz syndrome. N Engl J Med. 1994;330(23):1685-1686.
17. Mills K, Mandel H, Montemagno R, Soothill P, Gershoni-Baruch
R, Clayton PT. First trimester prenatal diagnosis of Smith-Lemli-Opitz
syndrome (7-dehydrocholesterol reductase deficiency). Pediatr
Res. 1996;39(5):816-819.
18. Honda M, Tint GS, Honda A, et al. Measurement of 3 beta-hydroxysteroid
delta 7-reductase activity in cultured skin fibroblasts utilizing ergosterol
as a substrate: a new method for the diagnosis of the Smith-Lemli-Opitz
syndrome. J Lipid Res. 1996;37(11):2433-2438.
19. Waye JS, Eng B, Nowaczyk MJ. Prenatal diagnosis of Smith-Lemli-Opitz
syndrome (SLOS) by DHCR7 mutation analysis.
Prenat Diagn. 2007;
27(7):638-640.
[PubMed: 17441222]
20. Irons M, Elias ER, Abuelo D, et al. Treatment of Smith-Lemli-Opitz
syndrome: results of a multicenter trial. Am J Med Genet. 1997;68(3):311-314.
21. Sikora DM, Ruggiero M, Petit-Kekel K, et al. Cholesterol
supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J
Pediatr. 2004;144(6):783-791.
22. Jira PE, Wevers RA, de Jong J, et al.
Simvastatin. A new
therapeutic approach for Smith-Lemli-Opitz syndrome.
J Lipid
Res. 2000;41(8):1339-1346.
23. Happle R. X-linked dominant chondrodysplasia punctata. Review
of literature and report of a case. Hum Genet. 1979;53(1):65-73.
24. Kelley RI, Wilcox WG, Smith M, Kratz LE, Moser A, Rimoin
D. Abnormal sterol metabolism in patients with Conradi-Hünermann-Happle
syndrome and sporadic lethal chondrodysplasia punctata. Am
J Med Genet. 1999;83(3):213-219. Erratum in: Am
J Med Genet 1999;84(4):387.
25. Braverman N, Lin P, Moebius FF, et al. Mutations in the
gene encoding 3 beta-hydroxysteroid-delta 8, delta 7-isomerase cause
X-linked dominant Conradi-Hünermann syndrome. Nat Genet. 1999;22(3):291-294.
26. Has C, Bruckner-Tuderman L, Müller D, et al. The
Conradi-Hünermann-Happle syndrome (CDPX2) and emopamil
binding protein: novel mutations, and somatic and gonadal mosaicism. Hum
Mol Genet. 2000;9(13):1951-1955.
27. Offiah AC, Mansour S, Jeffrey I, et al. Greenberg dysplasia
(HEM) and lethal X linked dominant Conradi-Hünermann chondrodysplasia punctata
(CDPX2): presentation of two cases with overlapping phenotype. J
Med Genet. 2003;40 (12):e129.
28. Mason DE, Sanders JO, MacKenzie WG, Nakata Y, Winter R.
Spinal deformity in chondrodysplasia punctata. Spine. 2002;27(18):1995-2002.
Review.
29. Happle R, Koch H, Lenz W. The CHILD syndrome. Congenital
hemidysplasia with ichthyosiform erythroderma and limb defects. Eur
J Pediatr. 1980;134(1):27-33.
30. Liu XY, Dangel AW, Kelley RI, et al. The gene mutated in
bare patches and striated mice encodes a novel 3beta-hydroxysteroid
dehydrogenase. Nat Genet. 1999;22(2):182-187.
31. König A, Happle R, Bornholdt D, Engel H, Grzeschik
KH. Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid
dehydrogenase, cause CHILD syndrome. Am J Med Genet. 2000;90(4):339-346.
Review.
32. Grange DK, Kratz LE, Braverman NE, Kelley RI. CHILD syndrome
caused by deficiency of 3beta-hydroxysteroid-delta8, delta7-isomerase. Am
J Med Genet. 2000;90(4):328-335.
33. FitzPatrick DR, Keeling JW, Evans MJ, et al. Clinical phenotype
of desmosterolosis. Am J Med Genet. 1998;75(2):145-152.
34. Andersson HC, Kratz L, Kelley R. Desmosterolosis presenting
with multiple congenital anomalies and profound developmental delay. Am
J Med Genet. 2002;113(4):315-319.
35. Waterham HR, Koster J, Romeijn GJ, et al. Mutations in the
3beta-hydroxysterol delta24-reductase gene cause desmosterolosis,
an autosomal recessive disorder of cholesterol biosynthesis. Am
J Hum Genet. 2001;69(4):685-694.
36. Brunetti-Pierri N, Corso G, Rossi M, et al. Lathosterolosis,
a novel multiple-malformation/mental retardation syndrome
due to deficiency of 3beta-hydroxysteroid-delta5-desaturase. Am
J Hum Genet. 2002;71(4):952-958. Erratum in: Am
J Hum Genet. 2003;73(2):445.
37. Krakowiak PA, Wassif CA, Kratz L, et al. Lathosterolosis:
an inborn error of human and murine cholesterol synthesis due to
lathosterol 5-desaturase deficiency. Hum Mol Genet. 2003;12(13): 1631-1641.
38. Greenberg CR, Rimoin DL, Gruber HE, DeSa DJ, Reed M, Lachman
RS. A new autosomal recessive lethal chondrodystrophy with congenital
hydrops. Am J Med Genet. 1988;29(3):623-632.
39. Hoffmann K, Dreger CK, Olins AL, et al. Mutations in the
gene encoding the lamin B receptor produce an altered nuclear morphology
in granulocytes (Pelger-Huët anomaly).
Nat Genet. 2002; 31(4):410-414.
[PubMed: 12118250]
40. Waterham HR, Koster J, Mooyer P, et al. Autosomal recessive
HEM/Greenberg skeletal dysplasia is caused by 3beta-hydroxysterol
delta 14-reductase deficiency due to mutations in the lamin B receptor
gene. Am J Hum Genet. 2003;72(4):1013-1017.